StockNews.com Downgrades Abeona Therapeutics (NASDAQ:ABEO) to Sell

Abeona Therapeutics (NASDAQ:ABEO) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Abeona Therapeutics Stock Down 7.0 %

ABEO opened at $3.17 on Tuesday. The firm has a market cap of $86.70 million, a PE ratio of -1.23 and a beta of 1.49. The business has a fifty day simple moving average of $7.43 and a 200-day simple moving average of $5.65. Abeona Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). On average, equities research analysts anticipate that Abeona Therapeutics will post -1.83 EPS for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Simplex Trading LLC boosted its position in shares of Abeona Therapeutics by 1,889.9% in the third quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 13,418 shares during the period. Jump Financial LLC acquired a new stake in Abeona Therapeutics during the fourth quarter valued at $199,000. Schonfeld Strategic Advisors LLC acquired a new stake in Abeona Therapeutics during the third quarter valued at $648,000. Worth Venture Partners LLC boosted its position in Abeona Therapeutics by 76.6% during the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 121,969 shares during the last quarter. Finally, Barclays PLC boosted its position in Abeona Therapeutics by 100.0% during the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after purchasing an additional 185,638 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.